Cargando…

A narrative review of new treatment options for chronic kidney disease in type 2 diabetes

Diabetic kidney disease is a frequent and costly complication to type 2 diabetes. After many years with a lack of successful trials there are now significant developments that will change treatment, guidelines and future outcome. Since the last two decades blockade of the renin-angiotensin system (R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Persson, Frederik, Borg, Rikke, Rossing, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106054/ https://www.ncbi.nlm.nih.gov/pubmed/33987414 http://dx.doi.org/10.21037/atm-20-4841

Ejemplares similares

Non-albuminuric chronic kidney disease in diabetes: A different approach?
por: Borg, Rikke, et al.
Publicado: (2022)

The Growing Challenge of Chronic Kidney Disease: An Overview of Current Knowledge
por: Borg, Rikke, et al.
Publicado: (2023)

Mitigating risk of aldosterone in diabetic kidney disease
por: Frimodt-Møller, Marie, et al.
Publicado: (2020)

Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease
por: Persson, Frederik, et al.
Publicado: (2019)

Chronic kidney disease in primary care: risk of cardiovascular events, end stage kidney disease and death
por: Borg, Rikke, et al.
Publicado: (2023)

Design and methodology of the PRIMETIME 1 cohort study: PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy
por: Jensen, Karina Haar, et al.
Publicado: (2023)

A Narrative Review of New Treatment Options for Diabetic Nephropathy
por: Pillai, Aadhira, et al.
Publicado: (2023)

Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture
por: Rossing, Peter, et al.
Publicado: (2021)

Rationale and design of a prospective, clinical study of kidney biopsies in people with type 2 diabetes and severely increased albuminuria (the PRIMETIME 2 study)
por: Møller, Marie, et al.
Publicado: (2023)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review
por: Persson, Frederik, et al.
Publicado: (2016)

Arterial Stiffness Is Associated With Cardiovascular, Renal, Retinal, and Autonomic Disease in Type 1 Diabetes
por: Theilade, Simone, et al.
Publicado: (2013)

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
por: von Scholten, Bernt Johan, et al.
Publicado: (2022)

New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease
por: Esposito, Pasquale, et al.
Publicado: (2020)

New options for the anemia of chronic kidney disease
por: Coyne, Daniel W., et al.
Publicado: (2017)

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment
por: Zobel, Emilie H., et al.
Publicado: (2019)

YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria
por: Rathcke, Camilla Noelle, et al.
Publicado: (2009)

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
por: Zobel, Emilie H., et al.
Publicado: (2017)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Current and emerging evidence-based treatment options in chronic migraine: a narrative review
por: Agostoni, Elio Clemente, et al.
Publicado: (2019)

Resistant Chronic Spontaneous Urticaria – A Case Series Narrative Review of Treatment Options
por: Khan, Sujoy, et al.
Publicado: (2022)

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907
por: Vistisen, Dorte, et al.
Publicado: (2021)

New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review
por: Losito, Angela Raffaella, et al.
Publicado: (2022)

Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes
por: Stougaard, Elisabeth Buur, et al.
Publicado: (2021)

Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study
por: Jaimes Campos, Mayra Alejandra, et al.
Publicado: (2023)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy
por: Persson, Frederik, et al.
Publicado: (2010)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial
por: Eleftheriadis, Theodoros, et al.
Publicado: (2017)

Effect of large weight reductions on measured and estimated kidney function
por: von Scholten, Bernt Johan, et al.
Publicado: (2017)

Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy
por: Broedbaek, Kasper, et al.
Publicado: (2011)

Diabetic neuropathy: A narrative review of risk factors, classification, screening and current pathogenic treatment options (Review)
por: Bondar, Andrei, et al.
Publicado: (2021)

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
por: Smeijer, J. David, et al.
Publicado: (2023)

Diabetic Gastroparesis and its Emerging Therapeutic Options: A Narrative Review of the Literature
por: Zahid, Shiza A, et al.
Publicado: (2023)

The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials
por: Zobel, Emilie H., et al.
Publicado: (2021)

Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy
por: Winther, Signe Abitz, et al.
Publicado: (2021)

Current and emerging treatment options for the elderly patient with chronic kidney disease
por: Fassett, Robert G
Publicado: (2014)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Treatment options for massive rotator cuff tears: a narrative review
por: Mancuso, Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tmn3k6b9b8oevskm18u2hm832m